NEWCaplight raises a $16M Series A, led by BlackRock and Fin Capital →
Skip to main content
Caplight Logo









Axent Biosciences

Axent Biosciences

Private
Berkeley, CaliforniaHealthcare & Life Scienceshttps://www.axentbio.com/

Last Round

Seed

Sep 20, 2024

Total Funding Raised

$10.1M

Company Overview

Axent Biosciences is a biotechnology company developing next-generation cell therapies using engineered biomaterials.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Advanced Materials, Drug Discovery, Clinical Trials

Business Model

B2B

Customer Profile

Government Contracts, Hardware Sales, Services & Consulting

AI Layer

Non-AI

Keywords

stem cell therapycell therapy manufacturingcell cultivation platformsynthetic biomaterialregenerative medicineParkinson's Diseasecell and gene therapystem cell manufacturingcell therapy CMCbiomaterial engineeringcell culture scaffoldpre-clinical biotechplatform technologyadvanced materials

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Axent Biosciences Comps

Public and private peers based on sector, stage, and business model.

Axent Biosciences comps — public and private peers by sector, stage, and business model
CompanyStatusEst. ValuationRev Multiple
OpenAIPrivate$86.0B~40x
CoherePrivate$5.0B--
Competitor 1Public$XX.XBXXx
Competitor 2Public$XX.XBXXx

View Full Comps Set

Access detailed peer comparisons, multiples, and valuation benchmarks.

Axent Biosciences Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
SeedSep 20, 2024
GrantJul 17, 2024
AcceleratorAug 18, 2020
View all Funding Rounds

Key People

Founding team and executive leadership

Hunter Johnson

Co-Founder and CEO

Founding Team

Axent Biosciences Investors

Notable investors and investment history

Axent Biosciences investors
InvestorRounds
Berkeley SkyDeckSeed, Accelerator
California Institute for Regenerative MedicineGrant
Berkeley Frontier FundSeed
Kerna VenturesSeed
View all Investors

Market signals

Structured signals derived from secondary market and firmographic data.

  • Sep 18, 2024

    Grew 25% QoQ, from 12 to 15 employees.

  • Aug 18, 2020

    $100K round from Berkeley SkyDeck

View all signals

Axent Biosciences Filings

SEC and related filings with document metadata.

Data table
TypedDateAmount OfferedAmount SoldFillingPagesDownload
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation
Sign Up to view
Mock Valuation

Axent Biosciences Filings

SEC and related filings with document metadata.

Frequently Asked Questions

Common questions about Axent Biosciences's valuation, stock price, and market status.

Firmographic Details

HeadquartersBerkeley, California
Employee Range14
Year Founded2019
Last FundingSep 20, 2024

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.